菠萝说：
PD1免疫药物很热，但它并不适合所有患者。后台最常收到的问题之一就是：PD1在XX癌里效果如何？一个个回答效率太低，最近干脆和朋友一起整理了大量论文数据，制作了一些图表，希望帮助大家真实了解PD1/PD-L1疗法的效果和进展，做出理性的选择。
感谢王昆和张继提供资料，感谢王慧mm绘图。王昆博士来自量子健康公司，运营着“肿瘤知道”公众号，欢迎大家关注（二维码见文末）。
PD-1和PD-L1免疫药物进展汇总
（来源：Global Oncology Trend 2017 : Advances, Complexity and Cost，Quintiles IMS）
PD-1和PD-L1免疫药物临床实验结果
注：图中数字为“客观缓解率”（ORR），可简单理解为肿瘤缩小超过30%的患者比例。
菠萝最后想强调3点：
1：请大家注意试验人数。如果只有几十位，说明是早期试验，随机因素较大，结果可能和后期结果有较大出入。
2：PD1/PDL1药物不止这三个。国产和进口都还有别的，我选择它们，是因为公布的数据最多。
3：本文并不是全部数据。免疫疗法现在有近千个临床试验正在进行，随时都有新数据出现。
肿瘤知道平台立志打造患者口袋中的简易工具，
广而告之
菠萝新书《癌症.新知：科学终结恐慌》正在当当网独家预售中。冯唐、李一诺、姬十三、魏坤琳，张晓龙联合推荐。
现在购买有特殊折扣，也会成为地球上第一批拿到书的人！欢迎长按下方二维码购买！有可以点击文末“阅读原文”。
购买《癌症.新知：科学终结恐慌》
点击下列关键词，直达您最关心的主题
免疫疗法 | 靶向药物 | 耐药 | PARP抑制剂 | 安慰剂
甲状腺 | 乳腺癌 | 肝癌 | 肺癌 | 白血病 | 鼻咽癌
参考文献：
1.in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016 Jun 30;374(26):2542-2452.
2.D'Angelo SP, Mahoney MR, Van Tine BA. A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401). J Clin Oncol 35, 2017 (suppl; abstr 11007) .2017 ASCO Annual Meeting.
3.Burgess MA, Bolejack V, Van Tine BA, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. J Clin Oncol 35, 2017 (suppl; abstr 11008). 2017 ASCO Annual Meeting.
4.Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab
5.Sylvia A, Sherene L, Deborah T, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. J Clin Oncol 35, 2017 (suppl; abstr 1088) . 2017 ASCO Annual Meeting.
6.Sylvia A, Peter S, Hope SR, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol 35, 2017 (suppl; abstr 1008). 2017 ASCO Annual Meeting.
7.Antoine H, Tim M, Kathleen NM, et al. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. J Clin Oncol 35, 2017 (suppl; abstr 5504). 2017 ASCO Annual Meeting.
8.Jan HS, Aurelien M, Susan Z, et al. Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol 35, 2017 (suppl; abstr 5514) . 2017 ASCO Annual Meeting.
9.Hamanishi J, Mandai M, Ikeda T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015 Dec 1;33(34):4015-4522.
10.Varga A, Piha-Paul SA, Ott PA, et al. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. J Clin Oncol 35, 2017 (suppl; abstr 5513). 2017 ASCO Annual Meeting.
11.Kang Y-K, Satoh T, Ryu M-H, et al: Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer. 2017 Gastrointestinal Cancers Symposium. Abstract 2. Presented January 19, 2017.
12.Charles S. F, Toshihiko D, Raymond WJ, et al.KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol 35, 2017 (suppl; abstr 4003), 2017 ASCO
13.Yung JB, Kei M, Charles SF, et al. KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. J Clin Oncol 35, 2017 (suppl; abstr 4012), 2017 ASCO
14.Toshihiko D, Sarina AP, Shadia IJ, et al. Pembrolizumab (MK-3475) for Patients with Advanced Esophageal Carcinoma: Preliminary Results from KEYNOTE-028. J Clin Oncol 33, 2015 (suppl; abstr 4010). 2015 ASCO
15.Ott PA, Piha-Paul SA, Munster P,et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 May 1;28(5):1036-1041.
16.Scott K, Sara L, Raymond S, et al. Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study. J Clin Oncol 35, 2017 (suppl; abstr 3548). 2017 ASCO
17.Scott K, Sara L, Raymond S, et al. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. J Clin Oncol 35, 2017 (suppl; abstr 3531). 2017 ASCO
18.FDA官网：https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm?platform=hootsuite
19.Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20.
20.Bendell JC, Kim WT, Goh BC, et a Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). Journal of Clinical Oncology 2016 34:15_suppl, 3502-3502
21.Vaena D, Grimm MO, Bracarda S, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322.
22.Peter H.O, Petros G, Arjun VB, et al. Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol 35, 2017 (suppl; abstr 4502)
23.Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015-1026.
24.Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20.
25.Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76.
26.Motzer RJ, Escudier B, McDermott DF, et al. CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.
27.El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502.
28.McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol. 2016 Mar 10;34(8):833-842.
29.Harrington K, Kasper S, Vokes EE, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856-1867.
30.Larkins E, Blumenthal GM, Yuan W, et al. U.S. Food and Drug Administration Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy. Oncologist. 2017 May 22. pii: theoncologist.2016-0496.
31.Delord JP, Hollebecque A, Boer JP, et al. An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). J Clin Oncol 35, 2017 (suppl; abstr 6025). 2017 ASCO Meeting.
32.Philippe A, John T, Alexander L, et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical hodgkin lymphoma: updated safety and efficacy results of a phase 1 study (ca209-039). Abstract release date: May 21, 2015) EHA Learning Center. Armand P. Jun 14, 2015; 103093.
33.Opdivo官网;Younes A, Santoro A, Shipp M, Zinzani PL,et al.Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort,single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283-94.
34.Chen R, Zinzani PL, Fanale MA, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 1;35(19):2125-2132.
35.Matthew DH, Patrick AO, Jon Z, et al.Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol 35, 2017 (suppl; abstr 8503). 2017 ASCO
36.Ott PA, Fernandez ME, Hiret S, et al. OA05.01 Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028. Journal of Thoracic Oncology , Volume 12,Issue1,S259
37.Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35.
38.Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
39.Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-1550.
40.Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer [published online October 9, 2016]. N Engl J Med. DOI: 10.1056/NEJMoa1606774.
41.Langer CJ, Gadgeel SM, Borghaei H, et al.Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17: 1497–1508.
42.Peters S, Gettinger S, Johnson ML, et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Jun 13:JCO2016719476.
43.Rittmeyer A, Barlesi F, Waterkamp D, et al, for the OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2016; published online Dec 12. http://dx.doi.org/10.1016/ S0140-6736(16)32517-X. Fehrenbacher L, Spira A, Ballinger M, et al, for the POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; published online March 9. http://dx.doi.org/10.1016/ S0140-6736(16)00587-0.
44.Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab orMonotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul 2;373(1):23-34.
45.Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015, 372(4): 320-330.
46.Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-384.
47.Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma.N Engl J Med 2015;372:2521-32.
48.Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-567.
49.Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol 35, 2017 (suppl; abstr LBA8507). 2017 ASCO.
点击下列关键词，阅读您关心的主题
免疫疗法 | 靶向药物 | 耐药 | PARP抑制剂 | 安慰剂
甲状腺 | 乳腺癌 | 肝癌 | 肺癌 | 白血病 | 鼻咽癌
联系客服
